Anti-apoptotic effects

Anti-apoptotic effects refer to the physiological or pharmacological processes that inhibit programmed cell death (apoptosis), thereby promoting cellular survival (Source: PMID 31034451). This term does not describe a specific molecular target like a receptor or enzyme; rather, it identifies a functional outcome mediated by several protein families, most notably the B-cell lymphoma 2 (Bcl-2) family and Inhibitor of Apoptosis Proteins (IAPs) (Source: UniProt). In oncology, many malignant cells evade death by overexpressing these anti-apoptotic factors, which allows them to survive despite genomic instability or chemotherapy-induced stress (Source: NIH). Consequently, therapeutic agents such as venetoclax have been developed to selectively inhibit specific mediators like the Apoptosis regulator Bcl-2, effectively neutralizing these survival signals to induce death in cancer cells (Source: PubChem). Conversely, in diseases characterized by excessive cell loss, such as neurodegeneration or myocardial infarction, research focuses on enhancing anti-apoptotic effects to preserve tissue function, though identifying specific and safe molecular activators remains a significant therapeutic challenge (Source: PMC7004653).

Other names

Apoptosis inhibitionProgrammed cell death inhibitionCell survival promotionSurvival-promoting effects

Modulation of programmed cell death by inhibiting anti-apoptotic proteins (such as Apoptosis regulator Bcl-2 or Induced myeloid leukemia cell differentiation protein Mcl-1) or by antagonizing Inhibitor of Apoptosis Proteins (IAPs) to facilitate caspase activation and mitochondrial outer membrane permeabilization.